Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 5/20 | 0.33 |
| ▸ | HTR2A | P28223 | 10/20 | 0.33 |
| ▸ | HTR2C | P28335 | 10/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2837226 | 0.83 | SLC6A2 (0.36) | CYP19A1TBXAS1 | |
| Hydrochloric Acid SCHEMBL10739252 | 0.81 | SLC6A2 (0.35) | CYP19A1TBXAS1 | |
| SCHEMBL2841248 | 0.77 | KDM1A (0.35) | HTR2A | |
| SCHEMBL2841889 | 0.75 | OPRM1 (0.35) | OPRK1HTR2AHTR2C | |
| SCHEMBL2840528 | 0.75 | CYP3A4 (0.36) | OPRK1 | |
| Hydrochloric Acid SCHEMBL2844001 | 0.74 | NPSR1 (0.31) | OPRK1HTR2AHTR2CL3MBTL1 | |
| SCHEMBL2837984 | 0.73 | OPRK1 (0.36) | OPRK1HTR2ACYP19A1TBXAS1 | |
| SCHEMBL2836631 | 0.73 | MAOA (0.35) | OPRK1HTR2AHTR2C | |
| SCHEMBL2841786 | 0.73 | OPRK1 (0.31) | OPRK1 | |
| SCHEMBL2836555 | 0.73 | KDM4E (0.38) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217031-B2 | Heteroaryl derivatives | NIPPON SHINYAKU CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100048537-A1 | HETEROARYL DERIVATIVES | NIPPON SHINYAKU CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2141168-A1 | HETEROARYL DERIVATIVES | Nippon Shinyaku Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048537-A1 | HETEROARYL DERIVATIVES | OPRD1, OPRM1, OPRK1 | OPRK1 3/4885HTR2A 28/4885HTR2C 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.